checkAd
    Biocryst Pharmaceuticals Aktie
    4,7510
     
    EUR
    -2,94 %
    -0,1440 EUR
    Letzter Kurs 08.05.24 Tradegate
    4,7170
     
    EUR
    1.200 STK
    Geldkurs 14:47:17
    4,8380
     
    EUR
    1.200 STK
    Briefkurs 14:47:17
    ISIN: US09058V1035 · WKN: 896047 · SYM: BO1 · USA

    Neueste Nachrichten

    BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO (berotralstat)
    13:00 Uhr · globenewswire · Biocryst Pharmaceuticals
    BioCryst to Present at Upcoming Investor Conferences
    07.05.24 · globenewswire · Biocryst Pharmaceuticals
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 06.05.2024
    06.05.24 · wO Chartvergleich · Agilent Technologies
    BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
    06.05.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    03.05.24 · globenewswire · Biocryst Pharmaceuticals
    Fokus Aktien mit extremen Handelsvolumen am Dienstag, den 23.04.2024
    23.04.24 · wO Chartvergleich · AGROB Immobilien
    BioCryst to Report First Quarter 2024 Financial Results on May 6
    22.04.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency
    17.04.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    03.04.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst to Present at Upcoming Investor Conferences
    25.03.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    05.03.24 · globenewswire · Biocryst Pharmaceuticals
    BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
    26.02.24 · globenewswire · Biocryst Pharmaceuticals